Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02554786 · ClinicalTrials.gov registry record · Phase 3
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,216
- Enrollment target
NCT02554786: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT02554786 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,216 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (187% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02554786, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,216 participants
- Enrollment target
Study Summary
The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 µg and QMF149 150/320 µg via Concept1) over two respective MF doses (MF 400 µg and MF 800 µg via Twisthaler® (total daily dose)) in poorly controlled asthmatic participants as determined by pulmonary function testing, and effects on asthma control
Primary Outcome
Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.
Interventions
- DRUG Mometasone furoate
- DRUG Indacaterol acetate/Mometasone furoate
- DRUG Salmeterol xinafoate/fluticasone propionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,216 participants |
| Start Date | 2015-12-29 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 3 |
What the finished NCT02554786 record still lists
NCT02554786 is an interventional study that assigns participants to a tested intervention. Its 2,216 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (187% higher).
The record links to 0 conditions, and to 3 interventions - of which Mometasone furoate is the first listed.
NCT02554786 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02554786 about?
NCT02554786 is a clinical study titled "A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma". The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 µg and QMF149 150/320 µg via Concept1) over two respective MF doses (MF 400 µg and MF 800 µg via Twisthaler® (total daily dose)) in poorly controlled asthmatic participants as determined ...
What is the current status of trial NCT02554786?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,216 participants. The study started on 2015-12-29. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT02554786?
The interventions under investigation include: Mometasone furoate (DRUG), Indacaterol acetate/Mometasone furoate (DRUG), Salmeterol xinafoate/fluticasone propionate (DRUG).
Who is sponsoring clinical trial NCT02554786?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02554786's enrollment target sits among peer trials
2,216 95th of 2000 higher than 1,906 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06831929 · 2,232 participants · NA
HPV Ends Here: Increasing Uptake of the HPV Vaccine
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI